For over 13 years, AWS has been the world’s most comprehensive and broadly adopted cloud platform. Millions of customers—including the fastest-growing startups, largest enterprises, and leading government agencies—trust AWS to power their infrastructure, become more agile, and lower costs.
CAS, a division of the American Chemical Society, is a scientific information solutions specialist. We provide curated, high-quality scientific data and expertise that fuel successful application of AI and other emerging technologies to enhance R&D efficiency and accelerate breakthroughs.
The Time for AI is Now
With the recent changes in healthcare, as we navigate through our “New Normal” it is now more crucial than ever to accelerate AI in drug discovery and development.
Working with the leading lights of the field, The AI in Pharma Summit is providing even more high-quality learning and networking opportunities than usual, but this time, through a truly interactive virtual experience.
With a limited number of passes available, there is a selective application process in place to attend this intimate conference. The result? A targeted, dynamic networking experience with fellow senior leaders from across pharma and biotech.
The recent impact of Covid-19 has brought into focus the opportunities AI presents to drug discovery and development. Attendees will be able to deep-dive into how these opportunities are being maximized in the preclinical and clinical arenas to help accelerate drugs through the pipeline.
The AI in Pharma Summit will provide you with a truly end-to-end learning experience. Through a variety of dynamic formats, such as exclusive case studies, interactive panels and discussion-led roundtables, you will be able to accelerate your understanding of the industry in just one day.
Through this virtual platform comes the opportunity to personalize your experience at The AI in Pharma Summit. Seamlessly switch between sessions, hop in and out of meetings, actively or passively take part in discussions and more are all possible depending upon your goals – and with no rushing around!
By going virtual, you will be able to see every audience member and instantly message them. Through the ability to book 1-2-1 meetings, virtual “hallway conversations” and open time for casual interactions the opportunity to meet your future partners and collaborators is at the heart of this event.
You will have exclusive access to content and opportunities, pre and post event. Before the event officially starts, you will be able to enter the virtual platform and start connecting with your fellow attendees. After the event, you will have access to on-demand presentations, session write-ups and other resources for six months.
Lihua joined H3 in 2011 and serves as President and Chief Data Science Officer, leading H3’s data science-focused precision medicine efforts and the company’s overall strategic business direction. An accomplished leader in the biopharmaceutical industry, Lihua has spent more than 20 years in computational biology and bioinformatics and has deep experience in cancer genomics and predictive biomarkers. This expertise allows her to integrate the bioinformatics discipline into H3’s drug discovery and patient selection focused translational science platforms. Prior to H3, Lihua spent 12 years with AstraZeneca’s research and development unit, helping to build and deliver the multinational pharmaceutical company’s oncology bioinformatics capabilities.
Lihua earned a Ph.D. from Boston University and a M.E. from Tsinghua University in Beijing, both in biomedical engineering. She received her B.E. in biomedical engineering and automation from Tsinghua University.
José is Global Head of Computer Aided Drug Discovery (CADD), part of
Global Discovery Chemistry at the Novartis Institutes for BioMedical
José joined Novartis in 2010. Previously he had been with the Schering-
Plough Research Institute and Merck Research Laboratories in Kenilworth, NJ, USA for 10 years where he had increasing responsibilities in the CADD
group. His scientific fields of expertise within computational chemistry
comprise molecular thinking, novel mode of actions, modeling, ab
initio calculations, molecular recognition, QM-MM methods, solvation and structure-based drug design. José is passionate about drug discovery.
He received his Ph.D. in Chemistry from the National University of
Córdoba, Argentina. He joined Prof. Tony Hopfinger’s group in the College of Pharmacy at the University of Illinois at Chicago as a Postdoctoral
Brian joined AbbVie in October of 2018 as the head of the newly formed RAIDERS team within Research & Development’s Information Research division, focused on accelerating, scaling, and amplifying the work of AbbVie’s R&D community using AI technologies like machine learning, deep learning, and cognitive computing. Brian came to AbbVie after spending five years in technology consulting across many industries, and over a decade of additional experience before that working in trading and financial markets technology. While his primary focus is AI technologies, his interests are much broader, and he has presented at multiple conferences on topics including optical networking, quantum computing, blockchain, cognitive architecture, and other emerging technology concepts that are all part of digital transformation.
Brian holds a B.S. degree in Computer and Cognitive Science from Alma College and a M.S in Computer Science from the University of Chicago.
Dr Williamson holds a DVM in animal dermatology and a PhD in human molecular and cellular dermato-pathology of autoimmune skin diseases from the University of Bern in Switzerland. She initiated her career at Novartis Pharmaceuticals in Switzerland where she had the opportunity to create and lead the Animal Dermatology Research group at Novartis Animal Health. Lina was later transferred to Boston in an international assignment to the Novartis Institutes for Biomedical Research (NIBR) as part of a cross-divisional business development team. She later joined NIBR’s Strategic Alliances team where she was responsible for leading the global outreach and scouting for innovation efforts from academic institutions, including academic incubators and startup companies. During that time, she developed interest on cutting edge technologies in the biomedical engineering field. That interest led her to join a startup company – Emulate Inc., derived from Harvard University’s Wyss Institute, focused on the development of Organs-on-Chips – and be part of the initial company creation team. Dr. Williamson joined the Brigham and Women’s Hospital in 2015, initially supporting the Brigham Research Institute as Innovation Strategists. Her entrepreneurial and strategic thinking & execution style, combined with more than twelve years of experience in the Pharma/Biotech industry, led her to take the challenge of create and establish the BWH Translational Accelerator, an initiative to support and speed up the transition of BWH’s innovation with commercial potential from bench to bed. Dr. Williamson currently serves as Founder, President & Chief Innovation Officer of the Translational Medicine Accelerator (TMA), a private biomedical development company formed to accelerate medical innovation that serves patients with unmet needs. Lina is also part of the NIH National Networks of Mentors in Entrepreneurship, a mentor for the post-doc program at Boston Children’s Hospital and supports entrepreneurship education programs from the Harvard Catalyst (Harvard Medical School).
Ryan Copping, a data scientist, is the global head of real world data science analytics at Genentech, which is part of Hoffmann-La Roche.
Gayle M. Wittenberg, Ph.D. is Director of Integrated Solutions and Informatics, Janssen Neuroscience and Head of Translational Research & Precision Medicine, Research IT. She has lead Janssen’s mood informatics initiatives, bringing together the best available datasets with state of the art analytics to identify and profile different biological and phenotypic subtypes of Major Depression as candidates for targeted therapies. Her work analyzing immunology and oncology trials for improvements in depressive symptoms led in part to running a proof of concept study of an immunology compound in depressed patients. In her Research IT role, she is working to bring about a new era of analytics that is more inclusive of data and less siloed to drive us to answer our most important questions using ‘all the data in the world’.
Dr. Wittenberg graduated summa cum laude with degrees in Physics and Electrical Engineering Physics at Oregon State University, and received her Ph.D. in Molecular Biology and Neuroscience at Princeton University where she studied computational neuroscience and learning in complex networks. She was a Princeton Council on Science and Technology Postdoctoral Teaching Fellow where she designed a new introductory biology course for physics and engineering students. She came to Janssen from Siemens Corporate Research where she headed the Personalized Healthcare group. While there, through mining genetic databases, she and her team designed PCR primers for the H1N1 flu within 3 days of the US outbreak, which outperformed those in use at the time. Previously she has worked at Trojan Nuclear Plant, installed the first computers used for electronic trading on the floor of the New York Stock Exchange working with Renaissance Technologies, spent a summer at Bell Labs recording birds singing in helium, and worked the salmon run in Naknek, Alaska.
Leonardo Rodrigues, Ph.D., is the VP of AI & ML at BERG, where he leads the development of analytics platforms and the analysis of projects in drug development, biomarker discovery and Health IT. He is a regular speaker in Pharma Analytics meetings, conducted workshops on best practices in data analysis, and is a reference in applying Bayesian AI and Advanced Analytics in the analysis of RWD and molecular data.
John Reynders, Ph.D. MBA, is Vice President, Data Sciences, Genomics, and Bioinformatics (DGB) at Alexion. In his role, Dr. Reynders leads the DGB organization in the design, building, and deployment of data-sciences solutions spanning R&D, Commercial, Strategy, and Business Development. These solutions include a graph-database of the entire rare-disease landscape annotated with prevalence, severity, clinical trial options, and genetic signature; a genomics-based rare-disease patient prevalence platform to inform licensing/acquisition opportunities; and AI-based phenotype- and genome-driven rare-disease diagnosis decision-support systems.
In parallel to his DGB responsibilities at Alexion, Dr. Reynders also led the R&D strategy, portfolio and project management department, leading efforts across R&D capability strategy, pipeline project management, portfolio optimization, governance, and R&D operating models. Prior to joining Alexion, Dr. Reynders served as CIO of Moderna Therapeutics, where he created a fully cloud-based biotech across all enterprise functions and developed informatics solutions to enable the design of messenger RNA therapeutics. Previously, John served as Vice President of R&D Information at AstraZeneca R&D leading teams in the US, UK, Sweden, Russia, Japan, and China to enable informatics and technology solutions across discovery, translational, clinical, pharmaceutical development, and regulatory functions. Before this, John served in leadership roles at Johnson & Johnson including VP Integrative Neuroscience and Biomarkers, Head of Informatics, and VP R&D Information Technology. Previously, John served as Information Officer with Lilly Research Laboratories, VP of Informatics at Celera Genomics, and held roles as Director and Program Manager at the Los Alamos National Laboratory.
Dr. Reynders received a Bachelors, Summa Cum Laude, in Mathematics from Rensselaer Polytechnic Institute, a PhD in Applied and Computational Mathematics from Princeton University, and a Masters of Business Administration from the Northwestern University Kellogg School of Management.
In his 10+ years of industry experience, Kausheek has held a variety of technical and management roles in consulting, telecom and pharma space. After completing his Bachelors in Electronics & Telecommunication Engineering at Manipal Institute of Technology- India, Kausheek was in various consulting roles with major global telecom companies for 5 years. Then he pursued MBA at Hult International Business School, Boston and joined Boehringer Ingelheim in 2012 where he has gained both depth and breadth of experience in pharma space.
Currently, Kausheek leads the Central Data Science, Americas team and RPA Community of Practice for Boehringer Ingelheim based in Ridgefield, CT, USA. His team focusses on data science use cases from all business areas in Human Pharma and Animal health. Prior to this role, he has led global projects in marketing and managed global Legal-IT team, improving company’s defensibility through robust workflows & smart technology adoption exploring AI Use Cases in Legal eDiscovery space.
Kausheek’s mantra is learn, unlearn and relearn with a passion for new and evolving technology, always looking to take smart risks. He’s been a speaker in major Technology events, volunteered as Judge in Connecticut Invention Convention, promotes STEM education in schools and associated with youth mentorship programs.
- Thursday, October 15th (EDT Timezone)
Enjoy your regular morning breakfast with your fellow attendees. Whether through pre-booked meetings, random interactions or in small groups, AI in Pharma Virtual Summit has got you covered.
Brian Martin, Head of AI, AbbVie
Representative from Amazon Web Services
Through the online polling system, you can pose your questions directly to the experts and vote for which questions you’d like to hear.
- Has the impact of Covid-19 changed how we view the potential of AI?
- After the Coronavirus pandemic, will AI get a strong foothold in drug R&D?
- How can AI help accelerate drug R&D during Covid-19 through Virtual Trials?
- What new challenges do we face given the changes over the past few months?
- How are organizations now deploying AI approaches compared to previously?
- Are we now on the cusp of an AI revolution in pharma?
- What do we hope to achieve by the end of this Summit?
Ryan Copping, Global Head of Analytics, Genentech
José Duca, Global Head, Computer-Aided Drug Discovery, Novartis
Reza Olfati-Saber, Global Head of AI and Deep Analytics, Sanofi
Lihua Yu, President, Chief Data Science Officer, H3 Biomedicine
Grab your coffee or tea and virtually meet up with folks from across the audience, whether it’s for a pre-booked meeting, casual chat or anything in-between, the choice is yours.
Personalize your experience by hopping in and out of sessions and meetings seamlessly.
- A look at how ML can be applied to unlock previously inaccessible biology in the pursuit of drugging RNA with small molecules
- Discover how Arrakis Therapeutics is developing transformative medicines for patients.
Donovan Chin, Director of Computational Drug Discovery, Arrakis Therapeutics
Nimit Jain, Head of Data Science, ACOE, Novartis
AI holds huge potential but there are many organizational challenges that are limiting progression. This roundtable will deep-dive into these strategic challenges, with open discussion on tactics as to how they can be solved.
Lina Williamson, Founder & Chief Innovation Officer, Translational Medicine Accelerator
AI is making an impact on drug discovery and development but data remains the be and end all when it comes to what can be achieved. This roundtable will deep-dive into the key challenges with data and how they can be overcome.
Led by Representatives from CAS, A division of the American Chemical Society
At last, an actual meal of your choice at a conference! Enjoy your lunch whilst connecting with old friends or new folks you have met from your interactions so far.
- As we understand the limits of Machine Learning, Bayesian AI brings new possibilities of how data can be analyzed
- How can Pharma and Healthcare benefit from a technology that generates new knowledge from data?
- We will discuss use cases in which Bayesian AI was successfully applied to Clinical Development and Health IT
Leonardo Rodrigues, Vice President, AI & Machine Learning, BERG Health
- An overview of how this branch of AI is being used to filter through ever-increasing volumes of text information to improve patient outcomes
- Witness examples of how NLP can find hidden medical insights that may have been otherwise overlooked
- Insight into the various areas of Healthcare that can NLP can be applied to increase clinical efficiency
AI-based models may not give the exact answer you’re looking for, therefore, that does not mean you have to apply the entire model to just one area. This roundtable will deep-dive into how you can apply different models and insights from these models across a variety of problems.
- Should you always apply a model in its entirety?
- How do you take insights from a certain model and apply them elsewhere?
- How can you use part of a model to generate the answers you are looking for?
- Sociologically, are people more comfortable with applying the whole model in the way it was intended to be used for a particular project?
- How can we work together as an industry to educate our colleagues on how to use models with flexibility?
Roundtable Leaders to be Announced
Catch-up with colleagues, pre-booked 1-2-1 meetings, make new connections… all are on the table!
Through the online polling system, you can pose your questions directly to the experts and vote for which questions you’d like to hear.
- What key data hurdles need overcoming before AI’s potential can be fully realized?
- How can we build trust in our AI approaches so users apply the predictions with confidence?
- What structured parameters do we need to set ourselves to define what “Good” and “Bad” data is?
- How can pre-competitive data sharing help with our data issues?
- How do we effectively dissect the massive amounts of data produced by AI?
- What do we hope the situation with regards to data looks like by the AI in Pharma Summit 2021?
John Reynders, Vice President, Data Sciences, Genomics, & Bioinformatics, Alexion Pharmaceuticals
Gayle Wittenberg, Senior Director, Neuroscience Data Science, Janssen
Camilo Zapata, Senior Director, Advanced/Predictive Analytics, Alkermes
Kausheek Nandy, Director, Head of Central Data Science, Americas, Boehringer Ingelheim
Brian Martin, Head of AI, AbbVie
Grab a glass of wine, beer or whichever drink you choose as you catch-up with old friends and make new connections, either 1-2-1 or in groups. Just because we are virtually meeting, doesn’t mean we can’t enjoy a one or two (or more) drinks together!
Roll straight into the rest of your Thursday, with no flight to catch!
Hosted on Hopin
Hopin, the Virtual Conference Platform for AI in Pharma will enable you to connect with your peers and learn from the pioneers of the industry, all from the comfort of your home office.
You will be able to completely personalize your experience to suit you, whether that’s jumping in and out of sessions on the agenda, booking 1-2-1 meetings at any time you like, passively or actively joining discussions and more are all yours to choose.
You will also be able to see everyone who has joined the event and instantly message them for formal and informal chats. Not only that, the Virtual Conference Platform will be open before the event to enable you to make more connections than ever before.
Partner With Us
Like you, here at GreyGreen we are adapting our plans in response to the ‘new normal’. As experts in curating fantastic audiences, we know that people still want to meet to learn and network with each other. The only difference is the “venue”.
As you adapt your marketing strategy, the same questions remain, how do you reach new prospects, demonstrate your capabilities, and build brand awareness? With GreyGreen you can be assured that our summits, either face to face or virtual, will deliver the audience you need to reach.
Connecting with your customer base has never been easier. We’ll bring our expertise to the table, advising you on how best to deliver your messaging and helping you prepare for the online experience. We use World-class software to ensure our summits are the best they can be.
Register for the Event
For pricing and booking options please click the button to go to the registration page.